Journal of Clinical Oncology
Articles in this Issue
A survival prediction model for veterans with advanced bladder cancer (BC) treated with immune checkpoint inhibitors (ICI).
855 Background: ICIs have been associated with improved survival for patients with BC and are now an integral part of the treatment paradigm. However, pre...
Association of androgen deprivation therapy and acute kidney injury in patients with prostate cancer: A systematic review and meta-analysis.
111 Background: Androgen deprivation therapy (ADT) has been associated with cardiovascular risk in prostate cancer patients. Thus, we performed a systemat...
Prospective monitoring of prostate specific membrane antigen (PSMA) –positive recurrent prostate cancer: Preliminary data from 6 months PSMA follow-up.
45 Background: PSMA imaging can identify recurrent prostate cancer after definitive surgery/radiation prior to detection on computed tomography (CT) or bo...
Circulating tumor cell expression analysis from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway).
199 Background: Approximately 25% of patients (pts) with prostate cancer have deleterious germline/somatic homologous recombination repair mutations (HRRm...
Association of PSMA PET results at biochemical recurrence (BCR) with metastasis free survival (MFS) by conventional imaging (CI) in patients with locally advanced or high-risk localized prostate cancer initially treated with radical prostatectomy (RP): A retrospective multicenter study.
355 Background: Prostate-specific membrane antigen (PSMA) positron emission tomography-computed (PET-CT) is used to stage prostate cancer (PCa) at BCR. PS...
Implementation of a digital multimedia tool for prostate cancer patient consultation.
345 Background: MyCareGorithm, is a digital health tool designed to improve the cancer consultation experience for patients, companions, and physicians. T...
Impact of bleomycin shortage in patients with advanced testicular non-seminoma germ-cell tumors: A middle-income country cancer center experience.
623 Background: Standard of care for advanced NSGCTs is BEP (bleomycin, etoposide, cisplatin). Social, epidemiologic and economic factors can impact drug...
Outcomes of enfortumab vedotin and pembrolizumab for patients previously treated with immune checkpoint inhibitors in the UNITE study.
867 Background: In trials testing enfortumab vedotin and pembrolizumab (EVP), prior treatment with immune checkpoint inhibitors (ICIs) was not permitted,...
Evaluating the efficacy and safety of pelvic lymph node dissection in high-risk prostate cancer patients undergoing radical prostatectomy: A systematic review and meta-analysis.
390 Background: Pelvic lymph node dissection (PLND) is currently considered the gold standard for lymph node staging in prostate cancer patients. However,...
Multimodal management of oligometastatic and oligoprogressive renal cancer patients with extra-lung metastases: The KAIROS study.
507 Background: Patients with oligometastatic (OM-) or oligoprogressive renal cell carcinoma (OP-RCC) may benefit from metastasis-directed therapy (MDT) a...
Population-based assessment of treatment patterns for high-risk localized prostate cancer.
349 Background: Patients diagnosed with high- or very high risk (H/vHR) prostate cancer (PCa) are at substantial risk of disease recurrence, metastasis, a...
Effectiveness and safety of RC48-ADC in combination with toripalimab as neoadjuvant treatment in HER2-positive muscular invasive urothelial bladder cancer patients.
710 Background: Bladder cancer with high expression of human epidermal growth factor receptor 2 (HER2) is associated with pathological malignancy and poor...
Patient characteristics and overall survival with lutetium (Lu <sup>177</sup> ) vipivotide tetraxetan ( <sup>177</sup> Lu-PSMA-617): A real-world analysis of early adopters.
63 Background: 177 Lu-PSMA-617, a prostate-specific membrane antigen (PSMA)-targeting radioligand therapy for metastatic castration-resistant...
Outcomes of patients with stage I testicular cancer following orchidectomy with borderline retroperitoneal lymph node enlargement at diagnosis.
633 Background: Approximately 60% of men diagnosed with testicular cancer present with Stage I disease. Most metastases occur in the retroperitoneal lymph...
Impact of tumor burden or focality in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer on response to treatment with UGN-102: A substudy of the phase 3 ENVISION trial.
776 Background: The ENVISION phase 3 study (NCT05243550) treated patients withlow-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC)...
Immune and inflammatory profiling in bladder cancer: Insights into biomarkers and therapeutic strategies.
861 Background: This study aimed to characterize and compare the profiles of inflammatory and immune responses (IFN-γ, CX3CR1, iNOS, PD-L1, CTLA-4, CD163,...
The evaluation of therapeutic outcomes of percutaneous US/CT-guided bipolar radiofrequency ablation for small renal masses under local anesthesia.
556 Background: This study is to evaluate the safety and feasibility of local anesthesia (LA) for percutaneous ultrasound/computed tomography (US/CT)-guid...
CD39 expression as a predictive biomarker for neoadjuvant treatment in muscle-invasive bladder cancer.
850 Background: Neoadjuvant therapy before radical cystectomy (RC) is the the standard treatment for muscle-invasive bladder cancer (MIBC). However, a sig...
CLARIFY: Positron emission tomography using <sup>64</sup> Cu-SAR-bisPSMA in patients with high-risk prostate cancer prior to radical prostatectomy—A phase 3 diagnostic performance study.
TPS429 Background: Prostate cancer (PC) is the second most prevalent cancer in men globally. In men with newly diagnosed, high-risk disease, PC most often...
Neoadjuvant darolutamide and relugolix combination preceding radical prostatectomy for high risk localized and locally advanced prostate cancer: A phase I/Ib trial.
TPS433 Background: Intensive androgen blockade with combination novel hormonal agent (NHA) + androgen deprivation therapy (ADT) appears promising as neoad...
Assessing the clinical impact of tumor volume on response to <sup>177</sup> Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer.
175 Background: 177 Lu-PSMA-617, a PSMA-directed radionuclide therapy, is an emerging treatment for metastatic castration-resistant prostate c...
Impact of androgen deprivation therapy with postoperative radiotherapy after radical prostatectomy on health-related quality of life.
133 Background: There is an ongoing debate on the use and duration of androgen deprivation therapy (ADT) with postoperative radiotherapy (RT) following ra...
Ethnic disparities in clinical trials for FDA-approved drugs in renal cell carcinoma: An analysis in the post-COVID-19-era (2020-2024).
452 Background: Ethnic and racial disparities in oncology clinical trial participation remain a pressing challenge. Despite initiatives by the NCI and FDA...
Prostate-specific antigen (PSA) response in Black patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) versus abiraterone acetate (ABI): A real-world comparison.
50 Background: Treatment for patients with mCSPC include androgen deprivation therapy (ADT) with the addition of androgen receptor pathway inhibitors (ARP...
Phenotypic and genetically predicted leukocyte telomere length and prostate cancer risk: Results from a large-scale longitudinal cohort study.
404 Background: Previous studies on the correlation between leukocyte telomere length (LTL) and prostate cancer (PCa) have shown contradictory results. Ou...